elevidys - Search News

News

Sarepta can begin shipping Elevidys therapy

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

· 13h

Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars

Fierce Pharma · 1d

FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault

Stocktwits on MSN8h

Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys

Shares of Sarepta Therapeutics Inc. (SRPT) traded 20% higher on Tuesday afternoon after the U.S. Food and Drug Administration ...

MIT Technology Review4d

The deadly saga of the controversial gene therapy Elevidys

The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.

Roche Says CHMP Issued a Negative Opinion on the Conditional Marketing Authorisation for Elevidys

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' gene therapy Elevidys for a type of rare ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results